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Propionyl-L-carnitine (PLC) is an SCFA esterified to carnitine that plays an important role in fatty acid oxidation and energy expenditure,
in addition to having a protective effect on the endothelium. In order to evaluate the effect of PLC on an animal model of obesity, insulin
resistance and, consequently, endothelial dysfunction, lean and obese Zucker rats (OZR) received either vehicle- or PLC-supplemented drinking
water (200 mg/kg per d) for 20 weeks. Body weight, food intake, systolic blood pressure and heart rate were controlled weekly and an oral
glucose tolerance test was performed. Fasting glucose, TAG, cholesterol, HDL, NEFA, adiponectin and insulin were analysed in serum.
Visceral adipose tissue and liver were weighed and liver TAG liver composition was evaluated. Endothelial and vascular functions were
assessed in the aorta and small mesenteric arteries by response to acetylcholine, sodium nitroprusside and phenylephrine (Phe); NO partici-
pation was evaluated after incubation with the NO synthase (NOS) inhibitor N G-nitro-L-arginine methyl ester (L-NAME) and endothelial
NOS protein expression by Western blotting. PLC decreased body-weight gain, food intake, adiposity, insulin serum concentration and
TAG liver content and improved insulin resistance. Aortae from OZR receiving either vehicle or PLC exhibited a lower contractile response
to Phe. PLC-treated OZR showed an enhanced release of endothelial NO upon the adrenergic stimulation. The protection of vascular
function found after treatment with PLC in an animal model of insulin resistance supports the necessity of clinical trials showing the effect
of L-carnitine supplements on metabolic disorders.
Propionyl-L-carnitine: Metabolic syndrome: Obese Zucker rats: Insulin resistance
Propionyl-L-carnitine (PLC) is an SCFA esterified to carnitine
that is rapidly transported into cells, in particular to the
mitochondria, where it is transformed into free carnitine
and propionyl coenzyme A(1,2). The latter is converted into
succinyl coenzyme A and finally to succinate, which is
involved in the citric acid cycle. Through this mechanism,
PLC supplies energy to ischaemic tissues(1,3). Carnitine
plays an important role in the transport of long-chain
fatty acids into the mitochondrial matrix, since it serves as
an essential substrate for the enzyme which catalyses the
initial step of b-oxidation, carnitine palmitoyltransferase 1.
These well-known roles of carnitine and PLC in fatty acid
oxidation and energy expenditure have led to the increase
of weight-loss and fitness products including L-carnitine
supplements. Nevertheless, the scientific data reporting the
effect of carnitine or PLC on obesity are scant. Obesity is a
medical disorder characterised by overweight and is associated
with co-morbidities such as hypertension, dyslipidaemia,
insulin resistance and diabetes. The frequent simultaneous
presence of these abnormalities led to the definition of the
metabolic syndrome as the presence of increased waist
circumference and two other cardiovascular risk factors:
serum glucose, hypertriacylglycerolaemia, low HDL and/or
hypertension(4). It is well established that obesity and the
metabolic syndrome impair the vasodilating properties of
the endothelium, leading to a dysfunction which, in turn,
can be considered the first step in the progression of CVD(5).
Lipid toxicity occurring in obesity, together with an insulin-
resistant state, may lead to an increased reactive oxygen species
generation and to a decreased NO production(6 – 8). These facts
altogether may be suggested as possible mechanisms respon-
sible for vascular functionality alterations in obesity. Our
research group has provided evidence of the protective
effect of PLC on endothelial dysfunction in hypertensive
rats(9,10) through a mechanism involving a decrease in reactive
oxygen species generation(11). Moreover, some studies carried
out with type 2 diabetic patients showed the efficacy of PLC
on peripheral arterial disease(12) and the improvement on
haemodynamic and metabolic markers after by-pass coronary
surgery(13). Based on these antecedents, the aim of the present
study was to evaluate the effect of an oral supplement of
PLC on an animal model of the metabolic syndrome, focusing
our attention on body-weight gain, lipid prolife, insulin
resistance and vascular and endothelial function.
* Corresponding author: Dr Maria Alvarez de Sotomayor, fax þ34 954556074, email aldesoto@us.es
Abbreviations: ACh, acetylcholine; HOMA-IR, homeostasis model assessment of insulin resistance; LZR, lean Zucker rats; NOS, NO synthase; OZR, obese Zucker
rats; pD2, 2log effective concentration that induces 50 % of maximal effect; Phe, phenylephrine; PLC, propionyl-L-carnitine; PLC-LZR, lean Zucker rats receiving
PLC-supplemented drinking water; PLC-OZR, obese Zucker rats receiving PLC-supplemented drinking water; SMA, small mesenteric arteries; W-LZR, lean
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Ten obese Zucker rats (OZR) and their ten littermate
controls, lean Zucker rats (LZR) (aged 12 weeks; Charles
River Laboratories, Barcelona, Spain), were housed at 248C
with 60 % relative humidity, on 12 h light and dark cycles
and were fed with a standard diet and water ad libitum.
LZR (n 10) and OZR (n 10) were divided into two groups
of five animals and received either vehicle (water; W-LZR
and W-OZR groups) or PLC-supplemented drinking water
(200 mg/kg per d; PLC-LZR and PLC-OZR groups). Both
PLC and vehicle were administered for 20 weeks. The
selected dose of PLC is reported to reduce body-weight gain
of hypertensive rats after a 56 d oral treatment(9).
Body weight, food intake, systolic blood pressure and heart
rate were evaluated weekly. Systolic blood pressure and heart
rate were measured by the ‘tail-cuff’ method with a pressure
meter (Niprem 645; Cibertec, Madrid, Spain). When the treat-
ment period finished, rats were anaesthetised and killed with
chloral hydrate 12 % intraperitoneally. Blood samples were
collected by intracardiac puncture for biochemical assays.
Visceral adipose tissue and liver were removed and weighed
and thoracic aorta and mesenteric vascular beds were isolated
for vascular reactivity studies. The protocol for animal
handling and experimentation of this investigation was in
accordance with the European Union European Community
guidelines for the ethical treatment of animals (European
Economic Community Directive of 1986; 86/609/EEC) and
was approved by the Ethical Committee for Animal Research
of the University of Seville.
Oral glucose tolerance test
After 18 weeks receiving vehicle or PLC, an oral glucose
tolerance test was performed by oral administration of glucose
(2 g/kg body weight) to LZR and OZR previously starved for
14 h. Blood samples were collected from the tail vein just
before and at 30, 90 and 180 min after the administration of
glucose. Plasma glucose concentration was determined using
a blood glucose commercial monitoring meter (Accutrendw
GCT; Roche Diagnostics, Barcelona, Spain).
Serum biochemical assays
Serum samples were obtained from blood by centrifugation
for 10 min at 3500 rpm and room temperature. Fasting
glucose, TAG, total cholesterol and HDL-cholesterol were
assessed by UV/visible spectrophotometry (Roche/Hitachi
Modular P; Roche Diagnostics GmbH, D-68298 Mannheim,
Germany). Plasma NEFA were measured by a commercial
ELISA kit (Wako Diagnostics, Richmond, VA, USA); adipo-
nectin and insulin were also measured by commercial ELISA
kits (Linco Research, St Charles, MO, USA). The homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated as previously described(14).
Measurement of liver TAG
For determination of hepatic TAG, liver tissue (200 mg)
was homogenised in 2 ml phosphate saline buffer with a
Polytron disrupter. The homogenate was centrifuged at 800 g
for 15 min, and the supernatant fraction was collected. TAG
in the supernatant fraction were measured with a commercial
kit (LabAssaye Triglyceride kit; Wako Diagnostics,
Richmond, VA, USA).
Assessment of vascular reactivity
Arterial preparation and mounting. Descending thoracic
aortae and branches II or III of small mesenteric arteries
(SMA) were dissected and placed in cold modified Krebs–
Henseleit bicarbonate solution of the following composition
(mM): NaCl, 118; KCl, 4·75; NaHCO3, 25; MgSO4, 1·2;
CaCl2, 1·8; KH2PO4, 1·18; glucose, 11. Then, aortic rings
(2–3 mm) and mesenteric segments (1·6–2·0 mm) were
mounted on myographs as previously described(9,10). Mechan-
ical activity was measured isometrically by a force-displace-
ment transducer (Pioden UF-1; Pioden Controls Ltd,
Canterbury, Kent, UK for the aortae; Multi Myograph
System-610M, Aarhus, Denmark for SMA) coupled to a
Powerlab data acquisition system (ADInstruments,
Melbourne, Vic, Australia). Contractile capacity of the vessels
was assessed with either phenylephrine (Phe, 1mM) or KCl
(80 mM) before relaxation or contraction experiments, respect-
ively. The presence of functional endothelium was assessed by
the ability of acetylcholine (ACh; 1mM) to induce more than
50 % relaxation of pre-contracted vessels.
Contraction and relaxation experiments. Aortic rings
were exposed to cumulative increasing concentrations of
Phe (1 nM to 10mM) to obtain concentration–response
curves. These concentration–response curves were assessed
in both the presence and the absence of functional endo-
thelium and in endothelium-intact arteries, after incubation
with the NO synthase (NOS) inhibitor N G-nitro-L-arginine
methyl ester (L-NAME; 300mM). Endothelium-dependent
and -independent relaxation was studied in aortic rings and
mesenteric segments by adding to pre-contracted arteries at
80 % of their maximal contraction cumulative concentrations
of ACh (1 nM to 10mM) and the NO donor sodium nitroprus-
side (0·1 nM to 1mM for aortae and 10 nM to 100mM for
SMA), respectively.
Fig. 1. Weight evolution of obese Zucker rats (OZR) and lean Zucker rats
(LZR) during 20 weeks of receiving either vehicle or propionyl-L-carnitine
(PLC). (W), OZR receiving water only (vehicle) (W-OZR); (X), OZR receiving
PLC-supplemented water (PLC-OZR); (K), LZR receiving water only
(W-LZR); (O), LZR receiving PLC-supplemented water (PLC-LZR). Data are
means for five animals per group, with standard errors represented by
vertical bars. *** Significantly different from W-LZR and PLC-LZR (P,0·001).
† Significantly different from W-OZR (P,0·05).
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Arterial homogenates were centrifuged at 1400 g for 10 min
at 48C, and the protein concentration of the supernatant
fractions was determined by the Bradford assay. A quantity
of 50mg protein was resolved by electrophoresis on 10 %
SDS-PAGE gels and then transferred onto nitrocellulose mem-
branes. Immunoblotting of individual proteins was
performed using a specific primary mouse endothelial NOS
antibody (0·4ml/ml; BD Biosciences, Franklin Lakes, NJ,
USA) at 48C overnight, which reacted with a peroxidase-
conjugated antibody.
Bands were visualised using the enhanced chemilumines-
cence assay (Pierce Chemical Company, Rockford, IL,
USA) and evaluated by densitometry. The sample loading
was verified by staining membranes with Ponceau red and
by immunostaining of smooth muscle a-actin with mono-
clonal mouse anti-a-actin antibody.
Drugs and chemicals
PLC was kindly provided by Sigma-Tau (Pomezia, Italy).
All the chemicals were purchased from Sigma Chemical Co.
(St Louis, MO, USA).
Expression of results and statistical analysis
Vascular contraction was expressed in g/mg dry tissue.
Relaxation induced by ACh was expressed as a percentage of
the maximal contraction. Areas under curves were analysed in
each individual concentration–response curve in the absence
or presence of functional endothelium in order to evaluate
its participation in the Phe-induced contraction. Sensitivities
to agonists were expressed as maximal effect (Emax) and pD2,
where pD2 ¼ 2log EC50 (where EC50 is the effective
concentration that induced 50 % of Emax). GraphPad Prism
3.0 software (San Diego, CA, USA) was used to calculate non-
linear regression equations and areas under curves. Two-way
ANOVA was used to compare concentration–response curves
to agonists. Differences between means were assessed with
Student’s t test for unpaired data. Differences were
considered significant when P,0·05. A StatView software
package version 5.0 (SAS Institute Inc., Cary, NC, USA) was
used for statistical analysis.
Results
Effect of propionyl-L-carnitine on weight values and food
intake
As expected, body, visceral adipose tissue and liver weights
were higher in PLC-OZR and W-OZR than in PLC-LZR
Table 1. Body and organ weights, food intake and haemodynamic parametres of animals
(Mean values with their standard errors)
W-LZR (n 5) PLC-LZR (n 5) W-OZR (n 5) PLC-OZR (n 5)
Mean SEM Mean SEM Mean SEM Mean SEM
Body weight (g) 422·71 8·61 437·40 11·57 570·70*** 10·59 526·30***† 17·02
Food intake (g/d per rat) 20·97 0·27 20·14 0·32 23·47*** 0·25 21·37††† 0·16
Visceral fat (g/kg) 0·13 0·01 0·12 0·01 0·40*** 0·01 0·34***† 0·02
Liver (g/kg) 0·31 0·02 0·29 0·01 0·42*** 0·01 0·45* 0·19
Systolic blood pressure (mmHg) 140·30 2·87 145·54 3·48 164·00*** 2·74 160·78** 3·58
Heart rate (beats/min) 435·91 11·58 424·37 10·16 351·86*** 7·51 377·59*** 20·61
W-LZR, water (vehicle)-treated lean Zucker rats; PLC-LZR, propionyl-L-carnitine-treated lean Zucker rats; W-OZR, water (vehicle)-treated obese Zucker
rats; PLC-OZR, PLC-treated obese Zucker rats.
Mean value was significantly different from those of the W-LZR and PLC-LZR: * P,0·05, ** P,0·01, *** P,0·001.
Mean value was significantly different from that of the W-OZR: † P,0·05, ††† P,0·001.
Table 2. Biochemical profile of animals
(Mean values with their standard errors)
W-LZR (n 5) PLC-LZR (n 5) W-OZR (n 5) PLC-OZR (n 5)
Mean SEM Mean SEM Mean SEM Mean SEM
Fasting glucose (mg/l) 1427 213·4 1341 114·9 1727 126·5 1710 326·4
Insulin (ng/ml) 0·22 0·10 0·14 0·02 1·63* 0·40 0·62**† 0·06
HOMA-IR 0·90 0·15 0·96 0·12 12·24** 2·89 4·65**† 0·62
Plasma TAG (mg/l) 651 100·7 645 78·1 3845·5*** 391·5 4506·2*** 560·3
Liver TAG (mg/l) 555 188 480 88 1632* 250 1007*† 33
NEFA (mmol) 7·09 1·68 11·88 11·52 23·41*** 1·46 29·26** 4·99
Cholesterol (mg/l) 1178 32·0 1231 39·7 2259·0*** 91·7 2544·0** 176·5
HDL-cholesterol (mg/l) 831 32·9 866 49·2 1182·0*** 63·1 1295*** 85·3
Cholesterol:HDL 1·40 0·07 1·42 0·08 1·78*** 0·04 1·68*** 0·06
Adiponectin (mg/ml per g fat) 1·15 0·19 1·14 0·02 0·54*** 0·05 0·59*** 0·03
W-LZR, water (vehicle)-treated lean Zucker rats; PLC-LZR, propionyl-L-carnitine-treated lean Zucker rats; W-OZR, water (vehicle)-treated obese Zucker rats;
PLC-OZR, PLC-treated obese Zucker rats; HOMA-IR, homeostasis model assessment of insulin resistance.
Mean value was significantly different from those of the W-LZR and PLC-LZR: * P,0·05, ** P,0·01, *** P,0·001.
† Mean value was significantly different from that of the W-OZR (P,0·05).
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and W-LZR (Fig. 1, P,0·001; Table 1, P,0·001). OZR, but
not LZR, receiving PLC showed a reduced body-weight gain
over the 20-week treatment compared with their vehicle-trea-
ted control groups (Fig. 1; P,0·05), which led to lower values
of PLC-OZR body and visceral adipose tissue weights at the
end of the study period (Table 1; P,0·05). No effect was
observed for liver weight after PLC administration (Table 1).
Consistent with these results, the food intake observed in
treated and non-treated OZR was higher than in the lean
groups (Table 1; P,0·001). Supplementation with PLC led
to a decreased food ingestion of OZR towards values similar
to those observed in LZR (Table 1; P,0·001). This dimin-
ution in the daily food intake was not observed in lean
PLC-treated animals (Table 1).
Effect of propionyl-L-carnitine on haemodynamic and
biochemical parameters
OZR receiving either vehicle or PLC showed higher systolic
blood pressure and lower heart rate than W-LZR and
PLC-LZR (Table 1; P,0·001). As shown in Table 2, fasting
glucose concentrations of PLC-OZR and W-OZR were
slightly higher than those found in PLC-LZR and W-LZR.
However, treated and non-treated OZR showed much more
increased insulin and HOMA-IR values than the lean groups
(P,0·05 and P,0·001). As a result, an insulin-resistant
state may be indicated in the obese animals. After the chronic
administration of PLC, both the insulin and the HOMA-IR
were lower compared with the OZR receiving the vehicle
(Table 2; P,0·05). This effect was not observed in the
PLC-LZR (Table 2). Plasma glucose concentrations obtained
in the oral glucose tolerance test were not significantly differ-
ent between the lean and obese or treated and non-treated
animals (Fig. 2(a)). However, the analysis of the area under
the plasma glucose curve revealed that W-OZR presented
a deteriorated glucose assimilation capacity compared with
W-LZR (Fig. 2(c); P,0·05). This capacity was recovered
after receiving PLC for 20 weeks (Fig. 2(c)).
Serum analysis revealed higher concentrations of TAG,
NEFA, total cholesterol and HDL-cholesterol and a higher
total cholesterol:HDL-cholesterol ratio in PLC-OZR and
W-OZR compared with the LZR groups (Table 2; P,0·01
and P,0·001). An identical lipid profile was found in
PLC-treated LZR and OZR when compared with the lean
and the obese control groups, respectively. As expected in
an insulin-resistant state, a more elevated liver TAG content
in treated and non-treated OZR was also found than in lean
animals (Table 2; P,0·05). This lipid liver fraction was
reduced in OZR, but not in LZR, by PLC-supplemented drink-
ing water (Table 2; P,0·05). Both PLC-OZR and W-OZR
showed lower plasma levels of adiponectin (Table 2;
P,0·001), which was not affected by PLC administration.
Effect of propionyl-L-carnitine on vascular and endothelial
functions of obese Zucker rats
Since metabolic effects were not observed in the PLC-LZR
group, vascular reactivity experiments only from the
W-LZR, W-OZR and PLC-OZR groups are described.
ACh induced concentration-dependent relaxation of both
aortae and SMA with intact endothelium (Fig. 3), but failed
to induce relaxation in endothelium-denuded arteries
(data not shown). W-OZR showed a deteriorated endothelial
function in the aorta, since a decreased response induced
by ACh was observed in this group when compared with
W-LZR (Fig. 3(a); P,0·05; pD2 ¼ 6·76 (SEM 0·04) and 7·14
(SEM 0·05), respectively). PLC supplementation was not
able to restore this dysfunction (Fig. 3(a); pD2 ¼ 6·80
(SEM 0·06)). As for SMA, neither obesity nor chronic PLC
administration affected the vasorelaxant response induced
by this muscarinic agonist (Fig. 3(c)).
The experiments developed with the NO donor sodium
nitroprusside revealed that endothelium-independent relax-
ation was not different between W-LZR and W-OZR both in
aortic rings (Fig. 3(b); pD2 ¼ 8·85 (SEM 0·07) and 8·87
Fig. 2. (a) Plasma glucose concentrations of starved lean Zucker rats receiv-
ing water (vehicle) only (K; W-LZR), obese Zucker rats receiving water only
(W; W-OZR), propionyl-L-carnitine (PLC)-treated LZR (O; PLC-LZR) and
PLC-treated OZR (X; PLC-OZR) after administration of glucose. (b) Change
in plasma glucose concentration during oral glucose tolerance test – base-
line plasma glucose concentration at time zero. (c) Areas under the curves
(AUC) of the change in plasma glucose concentration. Data are means for
five animals per group, with standard errors represented by vertical bars.
* Mean value was significantly different from that of the W-LZR (P,0·05).
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(SEM 0·01), respectively) and in SMA (Fig. 3(d); pD2 ¼ 5·73
(SEM 0·07) and 5·31 (SEM 0·05), respectively). Interestingly,
OZR receiving PLC showed an enhanced response induced
by sodium nitroprusside both in aortae (Fig. 3(b);
pD2 ¼ 9·25 (SEM 0·06); P,0·05 v. W-LZR) and SMA, in
particular, when lower concentrations of sodium nitroprusside
were used (Fig. 3(d); pD2 ¼ 6·00 (SEM 0·14); P,0·05 v.
W-OZR).
Both W-OZR and PLC-OZR showed a diminished response
to Phe (Fig. 4(b) and (c); maximal contraction effect
(Emax) ¼ 1·38 (SEM 0·11) and 1·28 (SEM 0·10), respectively)
when compared with W-LZR (Fig. 4(a); Emax ¼ 1·62
(SEM 0·12); P,0·05). PLC administration did not exert any
change in the Phe-induced contraction in obese animals.
As shown in Fig. 4, when functional endothelium was
removed, the contractile response induced by Phe increased
in all the groups, which indicates the participation of endo-
thelium-derived factors in the vascular function. If the differ-
ence between the areas under the curves in the presence or
in the absence of endothelium is calculated, the extent of
the participation of endothelium-derived factors in every
group can be ascertained. After analysing the difference
between areas under the curves in the presence or
in the absence of endothelium for each group, the highest
endothelium-derived factor participation was found in the
PLC-treated obese animals (Fig. 4(d); P,0·05).
Accordingly, pre-incubation with the NOS inhibitor
N G-nitro-L-arginine methyl ester (L-NAME) induced an
enhanced contraction to Phe in aortic rings from OZR (Fig. 5(c);
P,0·001) receiving PLC, but not in untreated obese animals
(Fig. 5(b)) or W-LZR (Fig. 5(a)), revealing an enhanced
participation of NO in the vascular response of arteries from
PLC-treated obese rats. Nevertheless, this effect was not
associated with changes in the endothelial NOS protein
expression in the aortae of these animals (Fig. 5(d)).
Discussion
The present study demonstrates that PLC (200 mg/kg)
supplementation administered to obese and insulin-resistant
animals is able to reduce body-weight gain, adiposity and
food intake. Furthermore, hyperinsulinaemia, liver TAG
Fig. 3. Concentration–response curves to acetylcholine (ACh; a and c) and to sodium nitroprusside (SNP; b and d) of aortae (a and b) and small mesenteric
arteries (SMA) (c and d) from obese Zucker rats receiving water (vehicle) only (W; W-OZR), lean Zucker rats receiving water only (K; W-LZR) or propionyl-L-carni-
tine-treated OZR (X; PLC-OZR). Data are means for five animals per group, with standard errors represented by vertical bars. * Significantly different from W-LZR
(P,0·05). † Significantly different from W-OZR (P,0·05).
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content and, therefore, the insulin-resistant state were partially
corrected by the treatment. On the contrary, neither TAG nor
cholesterol nor NEFA plasma concentrations were affected by
the ingestion of PLC. These effects were not observed in lean
animals. The present results suggest that adjunct therapy with
this compound may be useful for the treatment of patients with
the metabolic syndrome.
The metabolic syndrome is characterised by the
simultaneous occurrence of metabolic abnormalities including
obesity, glucose intolerance, dyslipidaemia and hypertension
that results in an increase of cardiovascular morbidity and
mortality(4). The OZR is a common animal model for the
study of obesity and the metabolic syndrome. These animals
are characterised by overweight, hyperlipidaemia, hyper-
phagia and hyperinsulinaemia(15) and several studies have
found that they develop mild hypertension at age 22–25
weeks(16 – 18). In addition, these animals exhibit impairment of
endothelium-dependent vasodilatation(18,19) and enhancement
of adrenergic tone(20).
The present results confirmed the presence of endothelial
dysfunction and the development of hypertension at the age
of 32 weeks. In contrast to that found in hypertensive
animals(9 – 11), PLC administration was not able to restore
ACh-induced relaxation, which is a common tool to evaluate
the capacity of endothelial cells to release vasoactive sub-
stances, such as NO or cyclo-oxygenase-derived products.
Nevertheless, concentration–response curves to Phe revealed
a greater difference among the contraction of endothelium-
intact and denuded aortae in PLC-treated obese rats. This
result suggests an enhancement in the release of endothelial
vasodilator factors upon adrenergic stimulation. In addition,
an enhanced response to low concentrations of the NO
donor was found. Similar findings were reported in hyperten-
sive rats, being then associated with the increase in NO
participation in Phe-induced contraction(9,10). In fact, an
enhanced participation of this important endothelium-derived
vasodilator factor was exclusively shown by OZR after
receiving PLC-supplemented drinking water.
Fig. 4. Concentration–response curves to phenylephrine (Phe) of aortae from (a) lean Zucker rats receiving water (vehicle) only (W-LZR), (b) obese Zucker rats
receiving water only (W-OZR) and (c) propionyl-L-carnitine-treated OZR (PLC-OZR). Curves were done in the absence of functional endothelium (X; PheE(2 ))
or in the presence of functional endothelium (W; PheE(þ )). Curves in the presence of functional endothelium were taken as the control. Significantly different from
the control: * P,0·05, ** P,0·01, *** P,0·001. † Significantly lower response compared with that of W-LZR in (a) (P,0·05). (d) Contribution of the endothelium
to the effect of Phe, calculated as the difference among areas under curves (AUC) to Phe in the absence and in the presence of functional endothelium.
† Mean value was significantly different from that of the W-OZR (P,0·05). All data are means for five animals per group, with standard errors represented by
vertical bars.
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Adiponectin is an abundant plasma protein secreted from
adipocytes that elicits protective effects in the vasculature
and myocardium. In obesity and insulin-resistant states, adipo-
nectin levels are reduced and loss of its protective effects
might contribute to the excess cardiovascular risk observed
in these conditions. Some of the described mechanisms by
which adiponectin exerts its protective action are the enhance-
ment of NO production and the suppression of reactive oxygen
species production in endothelial cells and the protection of
these cells from inflammation(21). Nevertheless, PLC adminis-
tration was not able to improve the adiponectin secretion by
adipocytes in obese animals, being the improvement of endo-
thelial function found after PLC treatment non-related to the
changes in this adipokine.
Other facts, such as antioxidant properties of PLC(22), may
be more likely to be involved in the enhancement of NO par-
ticipation found after administration of this compound. PLC is
able to reduce superoxide production in arteries, linked to the
increase of Cu/Zn-superoxide dismutase expression(11), which
may contribute to prevent NO degradation by superoxide
anions. In addition, several studies have confirmed that PLC
was able to increase endothelial NOS expression as found in
both in vitro (23) and in vivo (10,11) experiments. In contrast,
as revealed by the results of the present study, PLC did not
exert any effect on this enzyme protein expression in obese
animals. A possible increase of endothelial NOS activity
may be considered, even though further studies would be
necessary to test this hypothesis.
Both the antioxidant properties and the enhancement of NO
bioavailability have been also put forward as part of the mech-
anism underlying the beneficial effects of PLC on peripheral
vascular disease(24). Clinical trials have shown that PLC
improves exercise performance and functional status in
patients with claudication without notable adverse events(25).
This compound has also shown some benefits in the cardiac
function of patients with congestive heart failure(26). Its ben-
efits to those pathologies have been related to the previously
described endothelial effects, but also to its metabolic proper-
ties. In this sense, PLC was able to enhance rates of glucose
and palmitate oxidation in diabetic hearts(27).
Altogether, these findings suggest that PLC may be
beneficial in obesity, insulin resistance and the metabolic
syndrome. In spite of these antecedents, there are not many
studies evaluating the effects of L-carnitine and its derivates
Fig. 5. Concentration–response curves to phenylephrine (Phe) of aortae from (a) lean Zucker rats receiving water (vehicle) only (W-LZR), (b) obese Zucker rats
receiving water only (W-OZR) and (c) propionyl-L-carnitine-treated OZR (PLC-OZR). Curves were done in the presence (X) or in the absence (W) of the NO
synthase (NOS) inhibitor N G-nitro-L-arginine methyl ester (L-NAME). Curves in the absence of L-NAME were taken as the control. *** Significantly different from
the control (P,0·001). (d) Endothelial NOS (eNOS) protein expression analysed by Western blotting in aortic rings. All data are means for five animals per group,
with standard errors represented by vertical bars.
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on this pathology. The most relevant finding was carried out in
obese mice and revealed that L-carnitine supplementation
relieves lipid overload and glucose intolerance by enhancing
mitochondrial efflux of excess acyl groups from insulin-
responsive tissues(28). The effects of PLC treatment could be
well related to the L-carnitine part of the compound, since
oral PLC administration led to the enhancement of L-carnitine
concentration in plasma(22). Nevertheless, we cannot exclude
those effects related to the propionylic part of the molecule.
Insulin resistance is not only an impaired ability to promote
glucose utilisation in insulin-sensitive tissues, but also a
deterioration of other insulin effects, such as the stimulation
of lipogenesis by the adipose tissue and the inhibition of lipo-
lysis. The main manifestations of this situation are increased
plasma glucose and insulin levels, as well as higher plasma
concentrations of NEFA that finally are stored as TAG in
the liver. The present results confirmed the reversal of glucose
intolerance and the prevention of insulin resistance, as the
improvement of hyperinsulinaemia and the decreased
HOMA-IR value found in obese animals receiving PLC
revealed. In addition, although no changes in the concentration
of NEFA were found, PLC administration was able to dimin-
ish the liver TAG content in obese animals. Finally, a decrease
in the daily food intake and likely consequent decreases in
body weight and visceral adiposity were found in fatty animals
receiving PLC, which may be directly related to the reduction
of hyperinsulinaemia, since the latter and hyperphagia are
associated situations(29).
In summary, we have shown that PLC treatment improved
insulin resistance, decreased body weight and adiposity and
protected vascular function in an animal model of the meta-
bolic syndrome. These and previous(28) outcomes support the
necessity of clinical trials showing the effect of L-carnitine
supplements on insulin-resistant and obesity states.
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